HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice.

Abstract
Glyburide's pharmacokinetics (PK) and pharmacodynamics have not been studied in women with gestational diabetes mellitus (GDM). The objective of this study was to assess steady-state PK of glyburide, as well as insulin sensitivity, beta-cell responsivity, and overall disposition indices after a mixed-meal tolerance test (MMTT) in women with GDM (n = 40), nonpregnant women with type 2 diabetes mellitus (T2DM) (n = 26), and healthy pregnant women (n = 40, MMTT only). At equivalent doses, glyburide plasma concentrations were approximately 50% lower in pregnant women than in nonpregnant subjects. The average umbilical cord/maternal plasma glyburide concentration ratio at the time of delivery was 0.7 +/- 0.4. Insulin sensitivity was approximately fivefold lower in women with GDM as compared with healthy pregnant women. Despite comparable beta-cell responsivity indices, the average beta-cell function corrected for insulin resistance was more than 3.5-fold lower in women with glyburide-treated GDM than in healthy pregnant women. Women with GDM in whom glyburide treatment has failed may benefit from alternative medication or dosage escalation; however, fetal safety should be kept in mind.
AuthorsM F Hebert, X Ma, S B Naraharisetti, K M Krudys, J G Umans, G D V Hankins, S N Caritis, M Miodovnik, D R Mattison, J D Unadkat, E J Kelly, D Blough, C Cobelli, M S Ahmed, W R Snodgrass, D B Carr, T R Easterling, P Vicini, Obstetric-Fetal Pharmacology Research Unit Network
JournalClinical pharmacology and therapeutics (Clin Pharmacol Ther) Vol. 85 Issue 6 Pg. 607-14 (Jun 2009) ISSN: 1532-6535 [Electronic] United States
PMID19295505 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Blood Glucose
  • Hypoglycemic Agents
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Glyburide
Topics
  • Adult
  • Area Under Curve
  • Aryl Hydrocarbon Hydroxylases
  • Blood Glucose (analysis)
  • Cytochrome P-450 CYP2C9
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Diabetes, Gestational (drug therapy)
  • Dose-Response Relationship, Drug
  • Female
  • Fetal Blood (chemistry)
  • Glyburide (pharmacokinetics, therapeutic use)
  • Humans
  • Hypoglycemic Agents (pharmacokinetics, therapeutic use)
  • Insulin Resistance
  • Insulin-Secreting Cells (drug effects, physiology)
  • Metabolic Clearance Rate
  • Monte Carlo Method
  • Pregnancy
  • Pregnancy Trimester, Third

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: